Frontline healthcare workers who are directly diagnosing, treating, or caring for patients with COVID-19 have increased risks for depression, anxiety, insomnia, and distress, according to a study from China.
Treatment with the serotonin-norepinephrine reuptake inhibitor venlafaxine in patients with obstructive sleep apnoea (OSA) does not yield significant improvements in the apnoea–hypopnea index and even appears to worsen sleep architecture, as shown in a study.
A once-daily triple therapy of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; ICS/LAMA/LABA*) in a single inhaler significantly reduces the risk of all-cause mortality compared with a dual therapy of UMEC/VI (LAMA/LABA) in chronic obstructive pulmonary disease (COPD) patients with a history of moderate or severe exacerbations, confirm the latest results of the IMPACT** study.
There is currently no definite evidence showing that two classes of antihypertensive medications — ACE inhibitors and ARBs* — are linked to increased risk of COVID-19 infection, leading experts say. On the contrary, what is clear is that stopping these medications simply because of concern over their perceived theoretical risk can come at a price of adverse cardiovascular (CV) events.
Use of noninvasive ventilation (NIV), similar to invasive mechanical ventilation (IMV), appears to lessen mortality but may increase the risk for transmission of the novel coronavirus disease (COVID-19) in healthcare workers, suggest the results of a study.
At present, there are no definitive treatments for COVID-19. More than 300 clinical trials are ongoing in the search for a cure. Some of the treatments being tested were previously used, with varying levels of efficacy, in the treatment of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS).